Bank of America Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock

AbbVie (NYSE:ABBV) had its price objective increased by stock analysts at Bank of America from $234.00 to $276.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 12.09% from the stock’s previous close.

Several other equities research analysts have also recently commented on the company. Morgan Stanley boosted their target price on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. HSBC restated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a report on Monday. Cantor Fitzgerald lifted their target price on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday. Piper Sandler reissued an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $262.81.

AbbVie Stock Down 1.5%

Shares of NYSE ABBV traded down $3.67 during trading on Friday, hitting $246.24. 2,472,784 shares of the company traded hands, compared to its average volume of 7,180,692. The firm has a market capitalization of $435.06 billion, a P/E ratio of 121.36, a P/E/G ratio of 0.83 and a beta of 0.30. The company has a 50-day moving average price of $224.54 and a 200-day moving average price of $221.06. AbbVie has a 1 year low of $184.63 and a 1 year high of $261.64.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the business posted $2.46 EPS. The company’s revenue was up 12.4% on a year-over-year basis. Research analysts predict that AbbVie will post 14.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Clarus Wealth Advisors boosted its holdings in AbbVie by 18.4% in the 2nd quarter. Clarus Wealth Advisors now owns 9,101 shares of the company’s stock valued at $2,300,000 after purchasing an additional 1,417 shares during the period. Generali Investments Management Co LLC increased its holdings in shares of AbbVie by 9.9% during the second quarter. Generali Investments Management Co LLC now owns 29,767 shares of the company’s stock worth $7,491,000 after purchasing an additional 2,671 shares during the period. E. Ohman J or Asset Management AB raised its position in shares of AbbVie by 3.7% in the second quarter. E. Ohman J or Asset Management AB now owns 62,362 shares of the company’s stock valued at $15,693,000 after buying an additional 2,250 shares in the last quarter. Orrstown Financial Services Inc. raised its position in shares of AbbVie by 37.6% in the second quarter. Orrstown Financial Services Inc. now owns 3,558 shares of the company’s stock valued at $895,000 after buying an additional 972 shares in the last quarter. Finally, Spinnaker Investment Group LLC boosted its stake in shares of AbbVie by 29.3% in the second quarter. Spinnaker Investment Group LLC now owns 3,577 shares of the company’s stock valued at $900,000 after buying an additional 811 shares during the period. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital raised AbbVie’s price target to $280 and kept an outperform rating, signaling confidence in further upside for the shares. RBC price target article
• Positive Sentiment: JPMorgan also lifted its target to $280 and maintained an overweight rating, reinforcing the view that AbbVie remains attractively valued relative to its growth prospects. JPMorgan price target article
• Neutral Sentiment: A recent comparison of Johnson & Johnson and AbbVie highlighted both companies’ Q1 2026 results and the different ways each is appealing to income investors, but it did not point to a major new catalyst specific to AbbVie. Comparison article
• Neutral Sentiment: AbbVie’s recent trading has been choppy, with the shares pulling back after a prior move higher, which may reflect profit-taking rather than any fundamental deterioration. Recent trading article
• Neutral Sentiment: West Pharmaceutical completed the SmartDose sale to AbbVie, a transaction that appears operationally supportive but is not likely to be a major immediate stock driver. SmartDose sale article

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.